company is in the clinical trial of phase 2 study for its allosteric antagonist of a calcium channel that impairs GBM progression. These calcium channels are small molecules having anti-cancer properties. The company has also developed a biocompatible hydrogel formulation that was successfully tested in mice where GBM cells were injected intracranially.

It was founded in 2019 and is based in Torres Vedras, Portugal.